Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 11_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 5_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 2_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 10_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 12_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatoti... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 6_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

“…</p>Conclusions<p>Patients with CTP B cirrhosis and T2DM receiving SGLT2i therapy experienced a significant improvement in renal, hepatic function, and glycemic control over 48 months compared to patients treated with insulin.…”

Data Sheet 1_Dietary seaweed extract mitigates oxidative stress in Nile tilapia by modulating inflammatory response and gut microbiota.docx by Muhammad A. B. Siddik (6569957)

Unraveling the immunosuppressive role of Elastase B produced by cystic fibrosis isolates of <i>Pseudomonas aeruginosa</i> in an organotypic 3D lung epithelial cell model by Merel Wauters (21333023)

“…Compared to the <i>lasB</i> mutant, the wild-type strain significantly decreased inflammation by degrading MCP-1, IL-1β, GM-CSF, and IL-8. …”

The role of exosomal hsa-miR-125b-5p and hsa-miR-320c as non-invasive biomarkers in high-radon areas of Kazakhstan by Akmaral Aripova (20575879)

“…</p> <p>Results revealed a 25.4-fold increase in hsa-miR-125b-5p and a 12.5-fold decrease in hsa-miR-320c in participants exposed to high-radon levels compared to controls. …”

Prediction plots showing (A) the increase of the rodent flea abundance was mostly likely influenced by species identity: <i>Xenopsylla brasilliensis, Pulex irritans</i>, and <i>Din... by Stella T. Kessy (18700173)

Gene expression of neurotransmitter pathways at 6 dp. by Morgan Barnes (7876373)

“…In the 24 hpf dnVDRa induced group we see a significant decrease in slc6a4b expression (p < 0.05). …”

The comparison of CD4⁺ count, CD4/CD8 ratio, and HIV RNA load levels. by Qinzhi Zhang (19871125)

Changes in best-corrected visual acuity and total area reduction ratio of the epiretinal membrane (ERM) during follow-up. by Su Hwan Park (15158181)

“…<p>(a) During the follow-up period, the stable group showed no significant change in visual acuity, whereas the progression group exhibited a decrease compared to baseline starting at 12 months, with greater changes than those in the stable group beginning at 6 months. …”

Variability in performance and response to task dynamics. by Daniel Ramandi (10047543)

“…(B) The analysis of trajectory variability, quantified as DTW distance of consecutive trials, showed a non-significant trend towards greater variability in zQ175 mice, peaking later compared to WT mice (RM two-way ANOVA, genotype p = 0.070 F(1, 20) = 3.660, trial p = 0.0005 F(4.291, 85.82) = 5.351, interaction p = 0.542 F(19, 380) = 0.9329). …”

Construction and in vitro activity evaluation of protein transduction domain-transactivator of transcription and <i>Candida antarctica</i> lipase B fusion proteins by Xinhua Fu (20714497)

“…Taken together, the pET28a-calB-Tat prokaryotic vector was generated, yielding a significant amount of the calB-Tat protein. …”